

## RZL-012 FOR LOCAL FAT REDUCTION

Eran Blaugrund, Alon Bloomenfeld

Company name: Raziel Therapeutics;

Website: [www.raziel-therapy.com](http://www.raziel-therapy.com)

CEO name: Alon Bloomenfeld;

CATEGORY: Biotech/Pharma

SESSION: The heart, the liver, the brain in concert: a year of revolutions in the cardiometabolic space

- o Executive Summary/Investment Rational: Raziel Therapeutics is a phase 3-ready pharmaceutical company developing RZL-012, a non-surgical injectable New Chemical Entity (NCE), for local fat reduction and body shaping

- o Core Technology: RZL-012 is administered via one or two multi-injection sessions directly into subcutaneous fat, disrupting cell membrane integrity and causing necrotic death of fat cells at the injected regions. By eliminating fat cells, RZL-012 effectively reduces fat volume and minimizes the dimensions of treated areas
- o Product Profile/Pipeline: Submental fat (SMF, “double chin”) reduction is Raziel’s most advanced program. A double-blind placebo-controlled phase 2b trial (N=151) in American subjects seeking SMF reduction successfully met both primary and secondary endpoints, demonstrating the safety and efficacy of RZL-012. After a productive End-of-Phase 2 (EOP2) meeting with the FDA we are now ready for phase 3. Studies in other body areas such as abdomen, flanks and thighs are initiating
- o Business Strategy: Raziel will offer a non-invasive, simple, inexpensive, and yet very effective option for local fat reduction. Raziel is developing RZL-012 in the US and is collaborating with Fosun pharma in the great China region
- o What's Next: Raziel plans to initiate 2 SMF phase 3 studies and a phase 2 abdominal fat reduction study in 2024